Table 2 Clinical information and CSF characteristics of validation cohorts of CIS patients
Cohort 3* - ELISA studies | Cohort 4** - proteomic studies | |||||
|---|---|---|---|---|---|---|
Characteristics | CIS → CIS | CIS → CDMS | P values | CIS → CIS | CIS → CDMS | P values |
n | 27 | 47 | - | 25 | 24 | - |
Age (years)a | 30.5 (7.4) | 31.3 (6.6) | 0.706 | 36.5 (12.4) | 34.2 (9.3) | 0.509 |
Female/male (% female) | 22/5 (81.5) | 30/17 (63.8) | 0.123 | 16/9 (64.0) | 17/7 (70.8) | 0.419 |
Follow-up time (years)a | 4.2 (2.8) | 8.8 (3.6) | 8.24 ± 10-7 | 3.2 (1.3) | 10.7 (16.5) | 0.034 |
Clinical presentation | ||||||
Optic neuritis | 16 (59.3) | 15 (31.9) | 0.146 | 8 (32.0) | 3 (12.5) | 0.333 |
Brainstem | 5 (18.5) | 12 (25.5) | 4 (16.0) | 6 (29.1) | ||
Spinal | 3 (11.1) | 16 (34.0) | 7 (28.0) | 10 (41.6) | ||
Others | 3 (11.1) | 4 (8.5) | 6 (24.0) | 4 (16.6) | ||
CSF cellsb | 0.0 (0.0-2.0) | 0.0 (0.0-4.0) | 0.250 | 2.0 (0.0-3.2) | 3.0 (1.7-9.5) | 0.037 |
Proteins (mg/dL)b | 30.0 (25.7-36.2) | 34.0 (27.0-40.0) | 0.297 | 28.0 (25.0-36.0) | 30.0 (25.0-40.5) | 0.753 |